recommeded site for you
harry uptodate
Neurology Science
Skin Care and Treatment
Clinical Diagnose
Medical Study
Liver Health Center
Kedokteran Umum
Information
Harry Mulyono

medical information up to date

Tuesday, January 20, 2009

ATTENTION DEFICIT/HYPERACTIVITY DISORDER

ATTENTION DEFICIT/HYPERACTIVITY DISORDER - Laura L. Novak, MD
BASICS
DESCRIPTION
• Behavior problem characterized by a short attention span, distractibility, low frustration tolerance, impulsivity, and hyperactivity. Attention deficit disorder (ADD) is ADHD without the impulsivity and hyperactivity.
• Can result in poor school performance, difficulty in peer relationships, and parent/child conflict
• System(s) Affected: Nervous
• Synonym(s): Attention deficit disorder; Hyperactivity
GENERAL PREVENTION
• Children are at risk for abuse, depression, and social isolation.
• Parents need regular support and advice.
• Establish contact with teacher each school year.
EPIDEMIOLOGY
• Predominant age
- Onset 7 years old
- Lasts into adolescence and adulthood
- 50% meet diagnostic criteria by age 4 years.
• Predominant sex: Male > Female (5:1); ADD without hyperactivity may be more common in girls
Incidence
5% of school-aged children
RISK FACTORS
• Family history
• Comorbid conditions (associated with, but not caused by)
- Learning disabilities
- Mood disorders
- Oppositional defiant disorder
- Conduct disorder
Genetics
Familial pattern
ETIOLOGY
Multifactorial
ASSOCIATED CONDITIONS
See "Risk Factors"

DIAGNOSIS
SIGNS AND SYMPTOMS
• The AAP guidelines recommend using the DSM-IV criteria to establish the diagnosis of ADHD.
• DSM-IV: 6 or more inattention criteria and/or 6 or more hyperactivity/impulsivity criteria. Symptoms must begin by age 7 years, be present for >6 months, and be noticed in 2 settings (e.g., home and school).
• Inattention
- Careless mistakes in tasks
- Difficulty sustaining attention
- Doesn't seem to listen
- Doesn't follow through or finish tasks
- Difficulty organizing tasks
- Avoids tasks that require sustained mental effort
- Loses things
- Easily distracted
- Forgetful
• Hyperactivity/Impulsivity
- Fidgets
- Difficulty remaining seated
- Runs or climbs excessively
- Difficulty playing quietly
- Acts as if "driven by a motor"
- Talks excessively
- Blurts out answers before question is complete
- Has difficulty awaiting turn
- Interrupts others
History
• Birth and development history
- Good psychosocial evaluation of home environment
• School performance history
TESTS
• Behavioral testing
- Behavior rating scales (Connors, others) should be completed by parents and teachers. They are repeated after therapy is started to gauge differences (DSM-IV criteria can be used).
- Testing for learning disability (e.g., dyslexia) through the school
Lab
Rarely needed, can check lead level
Diagnostic Procedures/Surgery
• Diagnosis is by DSM-IV criteria.
• Electroencephalogram not needed unless symptoms are highly suggestive of seizure disorder (e.g., absence seizures)
Pathological Findings
Motor tics can be present (e.g., cough, noises, twitching).
DIFFERENTIAL DIAGNOSIS
• Refer to DSM-IV (see References).
• Activity level appropriate for age
• Dysfunctional family situation
• Learning disability (e.g., dyslexia)
• Hearing/vision disorder
• Oppositional/defiant disorder (see DSM-IV)
• Conduct disorder (see DSM-IV)
• Lead poisoning
• Medication reaction (decongestant, antihistamine, theophylline, phenobarbital)
• Tourette syndromemotor tics and coprolalia
• Pervasive developmental delay (autism)
• Asberger syndromehigh functioning autism
• Absence seizures (attention deficit only)
TREATMENT
GENERAL MEASURES
• Parent/school/patient education
• Work closely with teacher.
• Avoid unproved therapies.
Diet
No dietary changes have been proven to help attention deficit/hyperactivity disorder.
MEDICATION (DRUGS)
First Line
The American Academy of Pediatrics has recommended in their guideline (1)[C] that stimulant medications should be the first line in treatment of ADHD. It also recommends that a second type of stimulant be tried if the first treatment fails. As of this writing, the FDA is considering applying a "black box" warning to stimulants based on some reported cases of sudden death seen in patients using stimulant medications.
• Stimulant
- Methylphenidate (Ritalin, Concerta, Metadate CD, Ritalin LA, others): Ritalin 5-20 mg in the morning, at noon, and at 4 pm; maximum dose 60 mg/d (short-acting); Concerta 18, 36, 54 mg in the morning; Metadate CD 40 mg in the morning; Ritalin LA 20, 30, 40 mg in the morning (long-acting)
• Precautions
- If not responding, check compliance and consider another diagnosis. (1)[C]
- Some children experience withdrawal (tearfulness, agitation) after a missed dose.
- Methylphenidate has become a drug of abuse and should be monitored carefully: 20 mg nongeneric has highest street value
- Drug holidays should only be given if family/peer relationships are not harmed.
• Significant possible interactions
- Stimulants may increase levels of anticonvulsants, selective serotonin reuptake inhibitors, tricyclics, and warfarin.
ALERT
Pregnancy Considerations
Medications used in ADHD are category Ccaution in pregnancy
Second Line
• Amphetamine (stimulant)
• Adderall carries a "black box" warning for potential drug abuse
- Adderall: 2.5-20 mg q4-6h
- Adderall XR: 5-30 mg every morning;  6 years
• Nonstimulant
- Atomoxetine carries a "black box" warning regarding potential exacerbation of suicidality (similar to selective serotonin reuptake inhibitors). Because of this, the manufacturer recommends weekly visits for 4 weeks, then every other week visits for four sessions, then every 12 week visits. Atomoxetine has also been associated with hepatic injury in a small number of cases, and the manufacturer recommends checking liver enzymes if symptoms (jaundice, fatigue, malaise) develop,
- Atomoxetine (Strattera); selective norepinephrine reuptake inhibitor; 0.5-2 mg/kg/d every morning (10 mg, 18 mg, 25 mg, 40 mg, 60 mg). Maximum dose 1.4 mg/kg/d or 100 mg/d, whichever is less.
- Slower onset of efficacy; gastrointestinal side effects and sedation. Not addictive
- Atomoxetine interacts with paroxetine (Paxil), fluoxetine (Prozac), and quinidine
• Other nonstimulant drugs (e.g., clonidine, tricyclic antidepressants, selective serotonin reuptake inhibitors): Due to the mixed efficacy and high side effects of these drugs, they are not recommended for use without a consultant.
FOLLOW-UP
PROGNOSIS
• May last through school years and into adulthood
• May become easier to control with increasing age
• Encourage career choices that allow autonomy and mobility
• With treatment, there is no increased incidence of delinquency unless other comorbid features exist (e.g., conduct disorder).
• Encourage parents to subtract 2 years from their child's chronological age when allowing privileges (e.g., treat a 16-year-old like a 14-year-old, delay driving until age 18).
COMPLICATIONS
• Untreated attention deficit/hyperactivity disorder can lead to failing school, parental abuse, social isolation, and poor self-esteem.
• If appetite poor, offer food morning and evening
• Some children experience withdrawal (tearfulness, agitation) after a missed medication dose.
PATIENT MONITORING
• Parent/teacher rating scales initially, in 2 weeks, and regularly
• Office visits to monitor side effects and efficacy: End point is improved grades, improved rating scales, acceptable family interactions, and improved peer interactions.
- Monitor growth and blood pressure.
REFERENCES
1. American Academy of Pediatrics (AAP) Clinical Practice Guidelinestreatment of schoolafed children with ADHD. Pediatrics. 2001;108(4):1033-1044.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Revised. Washington, DC: American Psychiatric Association; 2000.
3. Rappley, MD. Attention Deficit-Hyperactivity Disorder. N Engl J Med. 2005;352(2):165-173.
4. Brown RT, Amler RW, Freeman WS, et al. Treatment of Attention Deficit/Hyperactivity Disorder: Overview of the evidence. Pediatrics. 2005;115(6):e749-e757.
ADDITIONAL READING
Barkley RA. ADHD: A Handbook for Diagnosis and Treatment. 2nd ed. New York: Guilford Press; 1998.


No comments:

Post a Comment